BugBiome develops microbial solutions for agricultural and human pest protection, leveraging the microbiome and engineering biology to offer alternatives to conventional chemical insecticides. The company is advancing a pipeline of targets across human and agricultural pests and is specifically working on methods to control aphids. BugBiome completed the 2023 cohort of Accelerate@Babraham, gaining access to mentors, communal laboratories, and investor networks. The team plans to expand following the recent funding to accelerate product development. BugBiome emphasizes solutions that protect biodiversity while reducing reliance on synthetic and bio-accumulative chemicals. The company is based in Cambridge, UK. BugBiome develops pest repellents that leverage the skin microbiome, using natural bacteria to create long-lasting protection. The company says its work aims to help stop the spread of vector-borne diseases such as malaria and dengue. BugBiome participated in Discovery Park’s Discovery Spark life science programme and was selected as the overall winner based on promising business offering and extensive progress during the programme. As part of the prize it received a business support package worth over £100,000, including one year of free lab space at Discovery Park and a £50,000 investment from Discovery Park Ventures. The programme included in-person training on team building, business metrics, branding, networking and mentoring, and culminated in finalist pitches at the GIANT Health Healthcare Investment Show. BugBiome is based in Sandwich, UK and intends to use the programme’s tools and connections to further progress its business.

Total raised

$63M

Funding rounds

2

Latest round

Seed

Latest activity

Feb 2024